Impact at cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction

Cilostazol, an antiplatelet drug that also may inhibit smooth muscle prolif eration, was given together with aspirin after primary stenting to treat pa tients with acute myocardial infarction. In a randomized controlled trials of 50 patients, clinical and angiographic outcome at 6 months was significa ntly improved with cilostazol, depicting a significantly smaller late loss and/or loss index.